AGIO · XBRL financial data

Agios Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AGIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	203	0	14	27	36	54
Cost of goods and services sold	3	0	2	3	4	6
Research and development	367	257	280	296	301	340
Selling, general and administrative	149	121	122	120	157	180
Operating income (loss)	(316)	(378)	(389)	(391)	(426)	(472)
Interest income	7	1	13	—	—	—
Other income (expense)	0	14	7	6	6	2
Income tax expense (benefit)	—	—	0	0	44	(1)
Net income (loss)	(327)	1,605	(232)	(352)	674	(413)
Earnings per share, basic USD per share	(4.74)	26.55	(4.23)	(6.33)	11.86	(7.12)
Earnings per share, diluted USD per share	(4.74)	26.55	(4.23)	(6.33)	11.64	(7.12)
Weighted average shares, basic millions of shares	69	60	55	56	57	58
Weighted average shares, diluted millions of shares	69	60	55	56	58	58

Fiscal years (AGIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	127	203	139	88	76	89
Marketable securities	445	817	644	689	817	765
Marketable securities, non-current	98	266	314	29	638	310
Inventory	15	0	8	19	28	33
Prepaid and other current assets	24	40	39	35	40	44
Total current assets	637	1,064	833	834	966	942
Property and equipment, net	32	29	23	15	12	11
Right-of-use asset	85	75	65	54	43	30
Total assets	853	1,438	1,239	937	1,663	1,297
Accounts payable	27	17	19	10	17	18
Accrued liabilities	60	32	30	43	47	45
Total current liabilities	94	60	63	68	81	82
Lease liability, non-current	97	86	72	57	40	22
Total liabilities	453	146	138	126	122	104
Accumulated deficit	(1,843)	(239)	(471)	(823)	(149)	(562)
Total stockholders' equity	400	1,292	1,101	811	1,541	1,193
Total liabilities and equity	853	1,438	1,239	937	1,663	1,297
Common shares outstanding (cover page) millions of shares	70	55	55	56	57	59

Fiscal years (AGIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(327)	1,605	(232)	(352)	674	(413)
Stock-based compensation	75	54	49	45	43	53
Net cash from operating activities	(291)	(407)	(309)	(296)	(390)	(373)
Purchases of property and equipment	15	6	5	1	2	4
Net cash from investing activities	76	1,249	243	240	363	377
Proceeds from issuing common stock	0	0	—	—	—	—
Net cash from financing activities	262	(766)	2	5	14	9
Net change in cash	47	76	(64)	(51)	(12)	13

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Carisma Therapeutics	2.8	45	1.9*	41.8M	—	Q3 FY25 10-QSep 30, 2025
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.